MicroRNA-106b is involved in transforming growth factor β1–induced cell migration by targeting disabled homolog 2 in cervical carcinoma by unknown
RESEARCH Open Access
MicroRNA-106b is involved in transforming
growth factor β1–induced cell migration by
targeting disabled homolog 2 in cervical
carcinoma
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Abstract
Background: MicroRNA-106b (miR-106b) was recently identified as an oncogene participating in cancer
progression. Transforming growth factor β1(TGF-β1) is an indispensable cytokine regulating the local
microenvironment, thereby promoting cervical cancer progression. However, the roles of miR-106b in cervical
carcinoma progression and TGF-β1-involvement in the tumorigenesis of cervical cancer remain unknown.
Methods: The expression of miR-106b in human cervical specimens was detected by real-time PCR analysis and in
situ hybridization assay. The effect of miR-106b on cell migration was analyzed by scratch and transwell assays.
TGF-β1 was used to induce cell migration. The expression of the miR-106b target gene DAB2 in human cervical
tissues and cell lines were measured by qRT-PCR, western blot and immunohistochemistry. Dual-luciferase reporter
assay was used to identify DAB2 as a miR-106b-directed target gene.
Results: miR-106b was frequently up-regulated in human cervical carcinoma specimens and cervical cancer cell lines.
Over-expression of miR-106b significantly promoted HeLa and SiHa cells migration. Likewise, inhibition of miR-106b
decreased HeLa and SiHa cells migration. The multifunctional cytokine TGF-β facilitates metastasis in cervical carcinoma.
miR-106b inhibitor treatment decreased the TGF-β1-stimulated migration of HeLa and SiHa cells. DAB2, a predicted target
gene of miR-106b, was inhibited by TGF-β1 partly through miR-106b and was involved in TGF-β1-induced cervical cancer
cell migration. The expression of DAB2 was low in cervical cancer tissues, and negatively correlated with miR-106b
expression. Finally, DAB2 was identified as a miR-106b-directed target gene by dual-luciferase reporter assay.
Conclusion: Our data suggest that the TGF-β1/miR-106b/DAB2 axis may be involved in the pathogenesis of cervical
carcinoma.
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Background
Cervical cancer is the third most common malignant
tumor in women worldwide, with recently increasing in-
cidence among young women [1–3]. Parametrical infil-
tration and distant metastasis of refractory cervical
carcinoma critically affects the therapeutic effect and
prognosis, despite screening and surgical treatment
widely used in the early stages [4, 5]. Elucidating the mo-
lecular mechanism for the invasion and metastasis of
cervical cancer is urgently needed. Recently, microRNAs
(miRNAs) participating in cancer progression have been
a focus.
miRNAs are single-stranded RNAs of about 21–23 nt
that play roles in posttranscriptional regulation of target
genes in cancer development, cell proliferation, apop-
tosis and differentiation [6–9]. Our previous study of
miRNA and mRNA microarray first revealed miR-106b
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as a key node in the signal transduction pathway of cer-
vical cancer [10]. However, the biological functions of
miR-106b in cervical cancer have not been well
investigated.
miR-106b is a member of the miR-106b ~ 25 cluster,
which is homologous to the miR-17 ~ 92 cluster known
as an oncogenic miRNA family. A number of reports
have clarified that miR-106b is involved in the regulation
of invasion and migration in various human cancers.
Yang et al. showed that miR-106b is highly expressed in
gastric cancer, and its expression is negatively correlated
with the survival of patients; miR-106b significantly
reinforced the invasion and migration ability of gas-
tric cancer cells [11]. The high expression of miR-
106b was also associated with lymph node metasta-
sis in breast cancer. miR-106b promotes the activation
of Wnt signal and induces β-catenin to enter the nu-
cleus, thereby enhancing the ability of tumor cell in-
vasion and migration [12]. miR-106b has been shown
to participate in activation of the TGF-β/Smad signal-
ing pathway by inhibiting Smad7 protein expression
to intensify the epithelial mesenchymal transition
(EMT) in breast cancer cells [13].
Extensive studies showed that TGF-β1 produced by
cervical cancer cells, is a key regulator in the local
microenvironment, thereby promoting invasion and mi-
gration in cervical carcinoma [14, 15]. Here, we investi-
gated whether miR-106b can affect the migration of
cervical cancer cells induced by TGF-β1 and the mech-
anism. We found that miR-106b had high expression in
cervical cancer and promoted the migration of cervical
cancer cells. miR-106b was involved in TGF-β1-induced
cell migration by targeting DAB2 in cervical carcinoma.
The study further revealed the molecular mechanism of
cervical cancer cell migration.
Methods
Tumor specimens
We collected 19 cervical cancer and 19 normal tissue
samples from the Department of Obstetrics and
Gynecology, Peking University Third Hospital. The
tumor tissues were derived from patients with a diagno-
sis of cervical cancer according to the FIGO criteria.
The normal tissue samples were from patients with be-
nign gynecological diseases such as uterine fibroids and
chronic cervicitis. All patients voluntarily gave their
signed informed consent before the operation. This
study protocol was approved by the ethics committee
of Peking University Third Hospital. Fresh tissues
were stored in liquid nitrogen before RNA extraction.
Total RNA was isolated by using Trizol reagent. The
isolated RNA was dissolved in RNase-free water and
stored at −80 °C.
Cell culture, treatment and reagents
The human cervical cancer cell lines C33A, HeLa, SiHa
and Caski, which are kept in our lab, were cultured in
DMEM with 10 % fetal bovine serum and 100 mg/ml
penicillin/streptomycin at 37 °C in 5 % CO2 atmosphere.
Cells were treated with TGF-β1(PeproTech, Rocky Hill,
USA) at 5 ng/ml for the indicated times. Cell transfec-
tion involved use of Lipofectamine2000 (Invitrogen,
Carlsbad, CA, USA) with miRNA mimics and inhibitors,
pmir-GLO plasmid(Life Technologies) or DAB2 siRNA.
The primer sequences were for miR-106b, 5′-AAGTGCT
GACAGTG CAGATAA-3′, mature miR-106b mimic, 5′-
CAAAGUGC UCAUAGUGCAGGUAG -3′ and miR-
106b inhibitor, 5′-GUUUCACGAGUAUCACGUCC
AUC-3′(Ribobio, Guangzhou, China). The primer se-
quence for DAB2 siRNA was sense, 5′-AACAAA
GGAUCUGGGUCAATT-3′and antisense, 5′-UUGACC
CAGAUCCUUUGU UTT-3′ (GenePharma, Shanghai).
DAB2 and GAPDH antibody were purchased from Santa
Cruz Biotechnology (Santa Cruz, CA).
Real-time PCR
Total RNA was extracted by the conventional Trizol
method. Reverse transcription of RNA was performed
using miRcute miRNA cDNA (KR201)(TIANGEN,
Beijing). Mature miR-106b was detected by using a
miRNA miRcute fluorescent quantitative detection kit
(FP401) (TIANGEN, Beijing).
Western blot assay
Total protein was extracted and quantified by using the
BCA detection kit. Cells were lysed in 5 × loading buffer,
boiled for 5 min and denatured. Cell lysates (20 μg) were
separated by 10 % SDS-PAGE and transferred to nitro-
cellulose membranes, which were blocked with 5 % non-
fat milk and incubated with primary antibodies against
DAB2(1:1000, rabbit anti-human polyclonalantibody,
Santa Cruz Biotechnology, Santa Cruz, CA, USA) at 4 °C
overnight. The goat anti-rabbit secondary antibody
(ZSGB-BIO, Beijing) was incubated for 1 h at room
temperature. The membranes were exposed by use of lu-
minescent liquid (Millipore, Massachusetts, USA) in the
darkroom, dried naturally. The densitometry of protein
bands was quantified by use of Image J (NIH, Bethesda,
MD, USA).
Immunohistochemistry
The paraffin sections of tissues were dewaxed as routine.
Endogenous peroxidase of tissues was removed by 3 %
H2O2 for 10 min. The tissues were blocked for 30 min
by goat serum working fluid (ZSGB-BIO, Beijing) and
stained with anti-DAB2 antibody (1:200, Santa Cruz Bio-
technology, Santa Cruz, CA) at 4 °C overnight, then goat
anti-rabbitsecondary antibody (ZSGB-BIO, Beijing) for
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1 h at room temperature. The tissues were stained with
DAB color solution for an appropriate time (ZSGB-BIO,
Beijing), dehydrated, fixed and photographed. Next, we
conducted a semi-quantitative analysis by using Image-
Pro Plus 6.0. First, five randomly selected fields (400×)
of each stained section were photographed. The inte-
grated optical density (IOD) and mean density (IOD
SUM/area) value for positive areas of each photo were
calculated. The mean density of each sample was the
average of the mean density from five images. We fur-
ther compared the mean density of 19 cervical cancer
biopsy sections and 19 normal cervical tissues samples
by t-test analysis.
In situ hybridization
In situ hybridization was performed by use of the miR-
106b in situ hybridization labeling Kit. Paraffin sections
of cervical cancer tissue were deparaffinized. Endogen-
ous enzymes are inactivated by 3%H2O2. The exposure
of mRNA nucleic acid fragment involved use of 3 % cit-
ric acid diluted fresh pepsin incubated for 15 min. Then,
1 % formaldehyde fixed for 10 min. After prehybridiza-
tion for 4 h in a thermostat box at 38 °C, tissue was in-
cubated with 5′digoxigenin-labeled oligonucleotide
probe detecting miR-106b and hybridized overnight.
Then, tissues were washed several times and blocked for
30 min, then, incubated with anti-digoxigenin antibody
for 60 min at 37 °C. After rinsing, sections were incu-
bated with SABC and Biotin peroxidase, then, stained
with DAB color solution for the appropriate time and
counterstained with nuclear. The relative level of miR-
106b in cervical tissues was measured by Image-Pro Plus
6.0 as for the detailed content in immunohistochemistry.
Cell scratch and migration assays
In cell scratch assays, a 20-μl pipette tip was used to make
three parallel wounds and one vertical wound in each well
of 6-well plates with cells incubated at 1 × 106. Cells were
cultured in serum-free mediumand photographed by
inverted microscopy at 0 and 24 h. In the transwell assay,
cells were seeded in the upper chamber of Costar trans-
well culture plates (24-well plates, 8 μm) and cultured in
serum-free medium. DMEM with 20 % fetal bovine serum
Table 1 Clinicopathological Characteristics of Cervical
Carcinoma Patients

















SCC Squamous Cell Carcinoma, AC Adenocarcinoma, LN Lymph nodes
Fig. 1 High expression of miR-106b in human cervical tissues detected
by Q-PCR and in situ hybridization. a Real-time PCR analysis of the
mRNA expression of miR-106b in 19 human cervical carcinoma tissues
and 19 normal cervical samples. U6 small nuclear RNA was an internal
control. Each point represents 1 sample. The horizontal bar is the mean
and whiskers are SEM. **P< 0.01 (Mann–Whitney test). b In situ
hybridization of miR-106b in negative control and normal
cervical specimens and cervical carcinoma tissue. c Quantification
of In situ hybridization staining of 19 normal cervical
specimens and 19 cervical carcinoma tissues
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was added to the lower chamber. After 24 h, the chamber
was washed 3 times with 1 × PBS. The membrane in the
lower chamber was fixed in 4 % paraformaldehyde and
stained with crystal violet. The cells on the upper mem-
brane that did not migrate were wiped with a cotton swab.
The number of migrated cells was counted under a micro-
scope in at least five fields.
Dual-luciferase reporter assay
The DAB2 gene 3′UTR with 166 bp sequences including
predicted miR-106b binding sites was amplified by PCR
from human genomic DNA. The amplified sequences
were inserted into cloning sites of the pmir-GLO vector
at SacI and SalI sites and verified by sequencing. The
mutant DAB2 3′UTR vector was constructed in the dual
luciferase reporter gene pmir-GLO vector with miR-
106b matching nucleotides “GCACTTT” replaced with
“TATAGGG” (Life Technologies, Shanghai). HEK-293A
cells in 24-well plates were transfected with the wild-
type and mutant DAB2 luciferase reporter vector and
miR-106b mimics. Luciferase assays involved use of the
Luciferase Reporter Gene Assay Kit (Promega) and ac-
tivities were normalized to Renilla luciferase activity.
Statistical analysis
Data are expressed as mean ± SEM and were analyzed
by use of GraphPad Prism 5. Two groups were com-
pared by Student’s t-test, and multiple groups by One
Way ANOVA, with further two group comparison by
Multiple Comparison Test Tukey’s test. When the vari-
ance of the two groups was not homogeneous, non para-
metric tests were used. Correlations were examined by
Spearman correlation analysis. P < 0.05 was considered
statistically significant.
Results
1. miR-106b was up-regulated in human cervical
carcinoma
We evaluated the expression of miR-106b in 19 cervical
cancer and 19 normal cervical samples by quantitative
real-time PCR. The characteristics of patients are in
Table 1. The expression of miR-106b was significantly
upregulated in cervical cancer tissues, with relative mean
expression 6.21(P < 0.01) (Fig. 1a). In situ hybridization
revealed positive expression of miR-106b in cervical can-
cer tissue and interstitial tissue as compared with con-
trols (Fig. 1b, c).
Fig. 2 Overexpression or knockdown of miR-106b with mimic or inhibitor in cervical cancer cells. a Real-time PCR of the expression of miR-106b
in 4 human cervical cancer cell lines. The expression of miR-106b in C33A cells was a control. *P < 0.05, **P < 0.01, *** P < 0.001 compared with
vehicle. Data are mean ± SEM (n = 3). b miR-106b mimic (miR-106b) at four concentrations (10, 50, 100, 200 nm) was transfected into HeLa cells
to overexpress miR-106b. miR-NC was a negative control.**P < 0.01, ***P < 0.001 compared with vehicle. Data are mean ± SEM (n = 3). c miR-106b
inhibitor (anti-miR-106b) at four concentrations (50, 100, 150, 200 nm) was transfected into HeLa cells to knockdown miR-106b. anti- NC was a
negative control.**P < 0.01, ***P < 0.001compared with vehicle. Data are mean ± SEM (n = 3)
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2. miR-106b promoted the migration of cervical cancer
cells
miR-106b was highly expressed in the cervical cancer cell
lines HeLa, CaSki and SiHa(Fig. 2a). We subsequently
established effective cell models, to explore gain-of-
function and loss-of-function of miR-106b in human
cervical cancer. The most appropriate concentration was
obtained by using different concentrations of reagent to
overexpress or knockdown miR-106b with mimics or in-
hibitors, respectively, in HeLa cells. The miR-106b
mimic (50 nm) with increasing 30 times (Fig. 2b) or
miR-106b inhibitor (100 nm) with knockdown effi-
ciency at 90 % (Fig. 2c) was the optimal concentra-
tion to over-expression or knockdown of miR-106b.
We overexpressed or knocked down miR-106b by trans-
fecting the mimic 106b or inhibitor 106b, respectively, in
HeLa cells and examined wound healing (Fig. 3a, b).
Wound healing area was significantly decreased with miR-
106b knockdown for 24 h, by 27.8 % (18.6 ± 1.16 vs 25.5 ±
1.99 cm2, P < 0.05) (Fig. 3c) and was enhanced with miR-
106b overexpression, by 1.66-fold (25.8 ± 1.02 vs 15.5 ±
0.59 cm2, P < 0.01) (Fig. 3d).Transwell assay showed that
cell migration was significantly reduced with miR-106b
knockdown, by 26.5 % (67 ± 1 % vs 92 ± 4 %, P < 0.05)
(Fig. 3e) and was elevated with miR-106b overexpression,
by 1.46-fold (212 ± 9 vs 145 ± 7, P < 0.05) (Fig. 3f).
The role of miR-106b in SiHa cells was similar to that in
Hela cells. Overexpression of miR-106b promoted SiHa
Fig. 3 miR-106b promoted the migration of HeLa cells tested by scratch and transwell assay. HeLa cells were transfected with a miR-106b inhibitor
(anti-miR-106b) at 100 nm and b miR-106b mimic(miR-106b) at 50 nm. Scratch assay of cell migration with c miR-106b knockdown and d miR-106b
overexpression. Scratched cells were observed and photographed at 0 and 24 h under a microscope. Data are mean ± SEM(n = 3).*P < 0.05,**P < 0.01
compared to control. Transwell migration assay with e miR-106b knockdown and f miR-106b overexpression. Cells were transfected with miR-106b
inhibitor(anti-miR-106b) and miR-106b control inhibitor (anti-NC). The cells on the transwell chambers were fixed, dyed, observed and photographed
after culture for 24 h. Data are mean ± SEM(n = 3). *P < 0.05 compared to control
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cell migration, and knockdown of miR-106b inhibited the
cell migration (Fig. 4).
3. Knockdown of miR-106b inhibited TGF-β1-induced cell
migration in cervical carcinoma
TGF-β1 plays an important role in cervical cancer pro-
gression. Whether miR-106b is involved in TGF-β1-
induced migration of cervical cancer cells is unknown.
Our data showed that HeLa and SiHa cell migration was
increased with TGF-β1 as compared with controls (Fig. 5)
(P < 0.01). After inhibition of miR-106b, the number of
cells migration was greatly reduced as compared with
cells, treated with TGF-β1 alone (Fig. 5) (P < 0.05).
4. DAB2 was regulated by TGF-β1 and miR-106b
To understand how miR-106b was involved in TGF-β1-
induced cell migration in cervical carcinoma, we identified
the target genes of miR-106b by using TargetScan. The
TargetScan predictive algorithm identified DAB2 as a po-
tential target of miR-106b.
DAB2 has low expression in many human cancers and
was regulated by TGF-β1 in previous studies. Further-
more, the relationship between DAB2 and miR-106b re-
mains unknown.
We next identified the regulation of TGF-β1, miR-106b
and DAB2. The expression of miR-106b was doubled with
TGF-β1 treatment for 24 h (Fig. 6a). As well, the expres-
sion of DAB2 protein was increased with knockdown of
miR-106b in HeLa cells, for an inverse relation (Fig. 6b).
We further detected DAB2 expression with TGF-β1 treat-
ment and miR-106b inhibition. DAB2 protein expression
was decreased with TGF-β1 treatment. The TGF-β1
downregulated expression of DAB2 protein was closely re-
lated to miR-106b expression (Fig. 6c, d).
Fig. 4 miR-106b promoted the migration of SiHa cells tested by scratch and transwell assay. SiHa cells were transfected with a miR-106b inhibitor
(anti-miR-106b) at 100 nm. and b miR-106b mimics (miR-106b) at 50 nm. Scratch assay of cell migration with c miR-106b knockdown and d miR-106b
overexpression. Transwell migration assay with e miR-106b knockdown and f miR-106b overexpression. Data are mean ± SEM (n = 3).*P < 0.05,
**P < 0.01 compared to control
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Fig. 5 Knockdown of miR-106b inhibited TGF-β1-induced cell migration in cervical carcinoma. a HeLa cells were transfected with 100-nm miR-
106b inhibitor (anti-miR-106b) or miR-106b control inhibitor (anti-NC) for 24 h, then migration was induced with or without TGF-β1 (5 ng/mL) for
24 h. b Quantification of A.**P < 0.01, $$P < 0.01, #P < 0.05. c SiHa cells were transfected with 100-nm miR-106b inhibitor (anti-miR-106b) or miR-
106b control inhibitor (anti-NC) for 24 h, then migration was induced with or without TGF-β1 (5 ng/mL) for 24 h. d Quantification of C.**P < 0.01,
$$P < 0.01, #P < 0.05
Fig. 6 DAB2, a predicted target gene of miR-106b, was inhibited by TGF-β1 in part via miR-106b. a Real-time PCR analysis of mRNA expression of
miR-106b in HeLa cells with TGF-β1 treatment for 24 h. Data are mean ± SEM (n = 3). *P < 0.01 compared to control. b Western blot analysis of
protein level of DAB2 in HeLa cells transfected with miR-106b inhibitor (anti-miR-106b) or miR-106b control inhibitor (anti-NC). Data are mean ±
SEM (n = 3). *P < 0.05 compared to control. c Western blot analysis of DAB2 protein level in HeLa cells transfected with 100 nm miR-106b inhibitor
(anti-miR-106b) for 24 h, then with or without TGF-β1 (5 ng/mL) for 24 h; GAPDH was an internal control. d Quantification of C.*P < 0.05
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5. DAB2 was involved in TGF-β1-induced cell migration in
cervical carcinoma
We further explored the role of DAB2 in TGF-β1-induced
cell migration. The ability for cell migration was increased
with siRNA knockdown of DAB2, compared with controls
(Fig. 7a, b) (P < 0.01). After treatment with TGF-β1, the
number of migrating cells was obviously elevated as com-
pared with TGF-β1 alone (Fig. 7c, d) (P < 0.05).
6. Identification of DAB2 as a miR-106b-directed target
gene
We tested the expression of DAB2 in cervical tissues.
The mRNA expression of DAB2 in 19 cervical carcin-
oma samples was significantly reduced, by 79.1 %, to
0.21 ± 0.03, as compared with normal cervical tissues
(P < 0.01) (Fig. 8a). miR-106b level was negatively cor-
related with DAB2 level (R2 = −0.7744, P < 0.001)
(Fig. 8b). Immunohistochemistry revealed reduced DAB2
protein level in cervical cancer tissue (Fig. 8c, d).
To identify whether DAB2 is a miR-106b–directed tar-
get gene, we predicted the interaction site of 7 bp of
miR-106b and the candidate target gene DAB2 3′UTR
(Fig. 9a). The wild-type (WT) or mutant (Mut) DAB2 3′
UTR was inserted into the region downstream of the
Renilla luciferase gene in the pmir-GLO vector. On co-
transfection with miR-106b and DAB2-WT 3′UTR in
HEK-293A cells, luciferase activity was lower, by 55.4 %,
to 0.55 ± 0.07, as compared with controls (P < 0.01).
However, on co-transfection with Mut-DAB2-3′UTR,
luciferase activity did not differ from the control
(Fig. 9b).
7. Working model
The working model of miR-106b in cervical cancer is
shown in Fig. 10. miR-106b can directly target the deg-
radation of DAB2 protein. TGF-β1 inhibits the expres-
sion of DAB2 protein by up-regulating miR-106 partly.
The TGF-β1/miR-106b/DAB2 axis is involved in the mi-
gration of cervical cancer cells. In general, miR-106b is
involved in TGF-β1-induced cell migration by targeting
DAB2 in cervical carcinoma.
Discussion
The main factors affecting the clinical prognosis of
metastatic and recurrent cervical cancer have not been
revealed completely. Understanding the molecular
mechanism related to cancer processes is crucial to find
better strategies for refractory cervical cancer treatment.
Fig. 7 Knockdown of DAB2 promoted TGF-β1-induced cell migration in cervical carcinoma. a Scratch assay of cell migration in cells transfected
with DAB2-NC or DAB2 siRNA at 0 and 24 h. Data are mean ± SEM (n = 3).*P < 0.05 compared to control. b Transwell migration assay of cells
transfected with DAB2-NC or DAB2 siRNA at 24 h. Data are mean ± SEM(n = 3).*P < 0.01 compared to control. c HeLa cells were transfected with
DAB2-NC or DAB2 siRNA for 24 h, then migration was induced with or without TGF-β1 (5 ng/mL) for 24 h and quantification. d Quantification of
C. **P < 0.01, $P < 0.05, #P < 0.05
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miRNAs have been found to play a vital role in tumor
progression [6–9]. miR-106b was identified to be a
tumor promoting factor in breast cancer, hepatocellular
carcinoma and melanoma [16–18]. In gastric cancer,
miR-106b activates PI3K/AKT signaling by inhibiting the
expression of the tumor suppressor gene PTEN, which
leads to the down-regulation of cell adhesion molecule
E-cadherin, thereby promoting the migration of cancer
cells [11, 19]. However, the role of miR-106b in cervical
cancer has not been investigated. Our previous study
first found that miR-106b was a key factor in cervical
cancer development [10]. This study showed that miR-
106b was significantly upregulated in cervical cancer tis-
sues as compared with control tissue, and miR-106b
overexpression promoted the migration of HeLa and
SiHa cells, which suggests that miR-106b may have a
critical role in regulating infiltration and metastasis of
cervical cancer. Our data confirmed that miR-106b acts
as a tumor promoter in cervical cancer progression.
Accumulating evidence has indicated that multiple fac-
tors are involved in the invasion and metastasis of cer-
vical cancer, including human papilloma virus protein,
soluble cytokine and its ligand, cytoskeletal regulatory
factors, integrin and matrix metalloproteinase [20].
Among them, TGF-β1 is an important regulatory factor
in cervical cancer. TGF-β1 has been reported to be in-
volved in the EMT, focal adhesion kinase (FAK) activa-
tion, integrin αvβ3-induced expression at the cell
surface, enhanced adhesion between cells and the sur-
rounding tissue, and increased migration and invasion in
cervical cancer cells [21]. We found out whether miR-
106b was also involved in the progress of TGF-β1-
induced migration in cervical cancer cells. miR-106b
inhibitor treatment decreased the TGF-β1-stimulated
migration of cervical cancer cells. Previous study found
that miR-106b enhanced the migration in breast cancer
cells by activating the TGF-β/Smad signaling pathway
via degradation of Smad7 [13]. Our findings are consist-
ent with conclusions for breast cancer. Moreover, we re-
vealed the molecular mechanisms of miR-106b involved
in TGF-β1-induced cervical cancer cell migration.
miRNAs negatively regulate their target mRNAs by
the RISC complex, which leads to mRNA translation in-
hibition or degradation, for a wide variety of functions.
We then found target genes of miR-106b according to
the network map from our miRNA and mRNA
Fig. 8 DAB2 had low expression in cervical cancer tissues, and which was negatively correlated with miR-106b expression. a The expression of DAB2
in 19 human cervical carcinoma tissues and 19 normal cervical tissues (**P < 0.01) (nonparametric test with Mann–Whitney test). U6 small nuclear RNA
was an internal control. Each point represents 1 sample. The horizontal bar is the mean and whiskers are SEM. b Spearman correlation analysis of
DAB2 and miR-106b expression in 19 cervical cancer tissues.***P < 0.0001, R2 = −0.7744. c Immunohistochemistry of protein expression of DAB2 in
cervical tissues. Expression of DAB2 protein in a) normal ovarian tissue as a positive control, b) normal cervical tissues, c) cervical carcinoma tissues, and
d) negative control. d Quantification of immunohistochemical staining of 19 normal cervical specimens and 19 cervical carcinoma tissues.**P < 0.01
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microarray assays. In these predicted target genes, DAB2
is considered a candidate tumor suppressor gene for its
absent and reduced expression in various tumors
[22–25]. Moreover, downregulation of DAB2 could
enable TGF-β-mediated cell motility and tumor
growth in vivo [23, 26]. In this study, DAB2 was first
identified to have low expression in cervical cancer.
As well, DAB2 protein level was downregulated with
TGF-β1 treatment for 24 h. miR-106b was confirmed
to be involved in the effect of TGF-β1 by depleting
DAB2 protein. To be excited, knockdown of DAB2
enhanced TGF-β1-induced migration in HeLa cells.
Another important finding from this study was that
miR-106b directly targeted the 3′UTR of the DAB2 and
inhibited DAB2 expression as seen on double luciferase
reporter gene assay. As well, DAB2 expression was nega-
tively correlated with miR-106b expression in clinical tis-
sue samples and cell experiments. Hannigan et al. found
downregulation of DAB2 mRNA expression in human
squamous cell carcinoma and that DAB2 level was an
independent predictor of metastasis and poor prognosis
[26]. Studies showed that DAB2 protein as a tumor sup-
pressor inhibits cell growth in lung cancer, and miR-93,
which is homologous to miR-106b, can inhibit its func-
tion in regulating the DAB2 protein level [27]. These
studies support our findings in different aspects.
Conclusions
miR-106b is regulated by TGF-β1 and contributes to cell
migration by targeting DAB2 in cervical carcinoma. The
TGF-β1/miR-106b/DAB2 axis could provide further
insight into the pathogenesis of cervical carcinoma, and
miR-106b could be a biomarker and potential thera-
peutic target in cervical cancer.
Abbreviations
miRNAs: microRNAs; TGF-β: transforming growth factor-β; DAB2: disabled
homolog 2; PTEN: phosphatase and tensin homolog; WT: wild-type;
Mut: mutant; MCM7: minichromosome maintenance complex component 7;
SCC: squamous cell carcinoma; AC: adenocarcinoma; LN: lymphnode.
Competing interests
There is also no conflict of interest involved in this study.
Authors’ contributions
LG and ZL conceived and designed this project. YC was mainly responsible
for acquisition and analysis of data and writing manuscript. YZ participated
in guiding the design of this research. YG and KY collected human tissue
samples. All authors read and gave their approval for the final version of the
manuscript.
Acknowledgments
This work was supported by grants from the National Natural Science
Foundation of China (No.81472429, 81471893, 81270157) and National Basic
Research Program of China (973 Program, 2013CB933702, 2014CBA02003).
Received: 21 November 2015 Accepted: 10 January 2016
Fig. 10 miR-106b is involved in TGF-β1-induced cell migration by
targeting DAB2 in cervical carcinoma. The Large circle represents
one cervical cancer cell. The orange small circles represent many
TGF-β1 cell factors. The two small rectangular blocks on the circle
indicate the receptors of TGF-β1. The red rectangle represents
miR-106b. The blue oval represents DAB2 protein
Fig. 9 DAB2 was identified as a miR-106b-directed target gene. a
The predicted interaction site of miR-106b and candidate target gene
DAB2 3′UTR. b Luciferase assay of HEK-293A cells co-transfected with
miR-106b mimic and pGL-3-DAB2 plasmid (miR-NC and miR-106b with
DAB2-wt 3′UTR; miR-NC and miR-106b with DAB2-mut 3′UTR) after
24 h. Data are mean ± SEM(n = 3).**P < 0.01
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